[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334689-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334689-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","serum-protein-profiling-reveals-an-inflammation-signature-as-a-predictor-of-early-breast-cancer-survival","Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival","","Background Breast cancers show substantial heterogeneity in biology, immunology, and prognosis, and validated serum protein tools for early-stage patient outcome prediction remain lacking. Methods The study analyzed 521 early-stage breast cancer patients with a median follow-up of 8.9 years and included controls with fibroadenoma or atypical ductal hyperplasia. Proximity extension assays measured 92 inflammatory/immune-related proteins, with cancers split into discovery and validation cohorts. Results LASSO identified a nine-protein inflammation-related signature predicting multiple survival endpoints more accurately than traditional factors; a separate 17-protein model distinguished benign from malignant lesions. Conclusions Inflammation and immunity-associated serum proteins may improve early breast cancer prognostication and lesion classification.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/serum-protein-profiling-reveals-an-inflammation-signature-as-a-predictor-of-early-breast-cancer-survival/334689/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/serum-protein-profiling-reveals-an-inflammation-signature-as-a-predictor-of-early-breast-cancer-survival/334689.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problem does the study address in early breast cancer care?","Question",{"text":63,"@type":64},"Validated serum protein-based tools to evaluate prognosis in early breast cancer are currently unavailable. The study aims to develop and assess serum protein signatures for prediction.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were serum proteins measured and analyzed?",{"text":68,"@type":64},"A proximity extension assay quantified preoperative serum levels of 92 proteins linked to inflammatory and immune response processes. The invasive cancers were split into discovery and validation cohorts, and LASSO regression was used to derive prediction signatures.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about the prognostic value of the protein signatures?",{"text":72,"@type":64},"A nine-protein signature predicted multiple survival endpoints more accurately than traditional prognostic factors, and its prognostic power stayed relatively stable over time. A 17-protein model also showed potential to differentiate benign from malignant breast lesions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334689,1790124558,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Karihtala etal. Breast Cancer Research (2024) 26:61 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-024-01812-x](https://doi.org/10.1186/s13058-024-01812-x)  \nRESEARCH Open Access  \nSerum protein profiling reveals an   \ninflammation signature as a predictor of early breast cancer survival  \nPeeter Karihtala 1,2*†, Suvi-Katri Leivonen3,4†, Ulla Puistola5, Elina Urpilainen5, Anniina Jääskeläinen2, Sirpa Leppä 1,3,4† and Arja Jukkola6†  \nAbstract  \nBackground Breast cancers exhibit considerable heterogeneity in their biology, immunology, and prognosis. Currently, no validated, serum protein-based tools are available to evaluate the prognosis of patients with early breast cancer.  \nMethods The study population consisted of 521 early-stage breast cancer patients with a median follow-up of 8.9 years. Additionally, 61 patients with breast fibroadenoma or atypical ductal hyperplasia were included as controls. We used a proximity extension assay to measure the preoperative serum levels of 92 proteins associated with inflammatory and immune response processes. The invasive cancers were randomly split into discovery (n = 413) and validation (n = 108) cohorts for the statistical analyses.  \nResults Using LASSO regression, we identified a nine-protein signature (CCL8, CCL23, CCL28, CSCL10, S100A12, IL10, IL10RB, STAMPB2, and TNFβ) that predicted various survival endpoints more accurately than traditional prognostic factors. In the time-dependent analyses, the prognostic power of the model remained rather stable over time. We also developed and validated a 17-protein model with the potential to differentiate benign breast lesions from malignant lesions (Wilcoxon p \u003C 2. 2*10− 16; AUC 0 . 94) .  \nConclusions Inflammation and immunity-related serum proteins have the potential to rise above the classical prognostic factors of early-stage breast cancer. They may also help to distinguish benign from malignant breast lesions.  \nKeywords Blood, Breast cancer, Proteomics, Prognostic factor, Proximity-extension assay  \n\n| †Peeter Karihtala, Suvi-Katri Leivonen contributed equally. |\n| --- |\n| †Sirpa Leppä, Arja Jukkola contributed equally. |\n\n*Correspondence:  \nPeeter Karihtala  \n[peeter.karihtala@hus.fi](peeter.karihtala@hus.fi)  \n1Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, P. O. Box 180, Helsinki  \nFI-00029, Finland  \n2Department of Oncology and Radiotherapy, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland 3Applied Tumor Genomics, Research Programs Unit, Medical Faculty, University of Helsinki, Helsinki, Finland  \n4iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland 5Department of Obstetrics and Gynecology, Medical Research Center, Research Unit of Clinical Medicine, University of Oulu and Oulu University Hospital, Wellbeing Services County of North Ostrobothnia, Oulu, Finland 6Department of Oncology, Tampere Cancer Center, Faculty of Medicine and Health Technology, Tampere University Hospital, Tampere University, Tampere, Finland  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/","cbCaioolR49ayEXJ","https://ap.wps.com/l/cbCaioolR49ayEXJ","pdf",4964962,11,"English","## Background\n## Methods\n## Results\n## Conclusions\n## Keywords","[{\"question\":\"What problem does the study address in early breast cancer care?\",\"answer\":\"Validated serum protein-based tools to evaluate prognosis in early breast cancer are currently unavailable. The study aims to develop and assess serum protein signatures for prediction.\"},{\"question\":\"How were serum proteins measured and analyzed?\",\"answer\":\"A proximity extension assay quantified preoperative serum levels of 92 proteins linked to inflammatory and immune response processes. The invasive cancers were split into discovery and validation cohorts, and LASSO regression was used to derive prediction signatures.\"},{\"question\":\"What did the study find about the prognostic value of the protein signatures?\",\"answer\":\"A nine-protein signature predicted multiple survival endpoints more accurately than traditional prognostic factors, and its prognostic power stayed relatively stable over time. A 17-protein model also showed potential to differentiate benign from malignant breast lesions.\"}]","Serum protein profiling reveals an inflammation signature as a predictor of early breast cancer survival | PDF",1790007887,28]